Halozyme Therapeutics, Inc.HALONASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank57
3Y CAGR+7.0%
5Y CAGR+18.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+7.0%/yr
vs -18.4%/yr prior
5Y CAGR
+18.9%/yr
Recent deceleration
Acceleration
+25.4pp
Accelerating
Percentile
P57
Within normal range
vs 5Y Ago
2.4x
Strong expansion
Streak
5 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$81.49M+3.1%
2024$79.05M+3.5%
2023$76.36M+14.6%
2022$66.61M+86.7%
2021$35.67M+4.2%
2020$34.24M-75.7%
2019$140.80M-6.3%
2018$150.25M-0.3%
2017$150.64M-0.1%
2016$150.84M-